components of the Medicare hospital outpatient prospective payment system (OPPS).

The APC Panel meets up to three times annually. The Charter requires that the Panel must be fairly balanced in its membership in terms of the points of view represented and the functions to be performed. The Panel consists of up to 15 members, who are representatives of providers, and a Chair. Each Panel member must be employed full-time by a hospital, hospital system, or other Medicare provider subject to payment under the OPPS. The Secretary or the Administrator of the Centers for Medicare & Medicaid Services (the Administrator) selects the Panel membership based upon either self-nominations or nominations submitted by Medicare providers and other interested organizations. All members must have technical expertise to enable them to participate fully in the work of the Panel. This expertise encompasses hospital payment systems; hospital medical-care delivery systems; provider billing systems; APC groups, Current Procedural Terminology codes, and alpha-numeric Healthcare Common Procedure Coding System codes; and the use of, and payment for, drugs and medical devices in the outpatient setting, as well as other forms of relevant expertise.

The Charter requires that all members have a minimum of 5 years experience in their area(s) of expertise, but it is not necessary that any member be an expert in all of the areas listed above. For purposes of this Panel, consultants and independent contractors are not considered as representatives of providers. A Panel member may serve up to a 4-year term. A member may serve after the expiration of his or her term until a successor has been sworn in. All terms are contingent upon the renewal of the Panel by appropriate action before its termination. The Secretary re-chartered the APC Panel effective November 21, 2008.

II. Announcement of New Members

The Panel may consist of a Chair and up to 15 Panel members who serve without compensation, according to an advance written agreement. Travel, meals, lodging, and related expenses for the meeting are reimbursed in accordance with standard Government travel regulations. We have a special interest in ensuring that women, minorities, representatives from various geographical locations, and the physically challenged are adequately represented on the Panel.

The Secretary, or her designee, appoints new members to the Panel from among those candidates determined to have the required expertise. New appointments are made in a manner that ensures a balanced membership.

The Panel presently consists of the following 15 members and a Chair: (The asterisk [*] indicates a Panel member whose term expires on September 30, 2010.)

- Edith Hambrick, M.D., J.D., Chair
- Ruth L. Bush, M.D., M.P.H.
- Dawn L. Francis, M.D., M.H.S.
- Kathleen M. Graham, R.N., M.S.H.A., C.P.H.Q.
- Patrick Grusenmeyer, Sc.D., M.P.A., F.A.C.H.
- David Halsey, M.D.
- Judith T. Kelly, B.S.H.A., R.H.I.T., R.H.I.A., C.C.S.
- Michael D. Mills, Ph.D., M.S.P.H.*
- Agatha L. Nolen, D.Ph., M.S., F.A.S.H.P.
- Randall A. Oyer, M.S.
- Beverly Khnie Philip, M.D.*
- Daniel Pothen, M.S., R.H.I.A., CPHIMS, CCS, CCS–P, CHC
- Gregory J. Przybylski, M.D.
- Russ Ranallo, M.S.*
- Michael A. Ross, M.D., F.A.C.E.P.*
- Patricia Spencer-Cisek, M.S., A.P.R.N.-BC, A.O.C.N.®*

On March 26, 2010, we published a notice in the **Federal Register** entitled "Medicare Program; Request for Nominations to the Advisory Panel on Ambulatory Payment Classification Groups" (CMS–1570–N) requesting nominations to the Panel replacing Panel members whose terms would expire on September 30, 2010. As a result of that **Federal Register** notice, we are announcing five new members to the Panel. All five appointments are for 4-year terms commencing on October 1, 2010, as indicated below:

New panel members	Terms
• Kari S. Cornicelli, C.P.A., FHFMA	10/1/2010 through 9/30/2014.
• Brian D. Kavanagh, M.D., M.P.H	10/1/2010 through 9/30/2014.
• Scott Manaker, M.D., PhD	10/1/2010 through 9/30/2014.
• John Marshall, C.R.A., R.C.C., RT®	10/1/2010 through 9/30/2014.
• Neville B. Sarkari, M.D., FACP	10/1/2010 through 9/30/2014.

(*Note:* Dr. Kavanagh replaces Dr. Mills; Dr. Manaker replaces Dr. Philip; Dr. Sarkari replaces Dr. Ross; Ms. Cornicelli replaces Mr. Ranallo; and Mr. Marshall replaces Ms. Spencer-Cisek. They will all take the Oaths of Office at the winter 2011 APC Panel meeting. Therefore, the current APC Panel members are all invited to attend the 2010 late summer meeting since the new members' terms do not begin until October 1, 2010.)

III. Collection of Information Requirements

This document does not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995.

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: August 11, 2010.

Donald M. Berwick,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 2010–20306 Filed 8–19–10; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Scientific Management Review Board.

The NIH Reform Act of 2006 (Pub. L. 109–482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices

or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the Scientific Management Review Board (also referred to as SMRB or Board) is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Scientific Management Review Board.

Date: September 14–15, 2010.

Time: September 14, 2010, 8:30 a.m. to 5:30 p.m.

Agenda: The focus of this meeting will be on the deliberations of the Translational Medicine and Therapeutics working group and its respective stakeholder consultation. Presentation and discussion will include, but is not limited to, representatives from academia, government, industry, venture capital firms, and patient advocacy groups. Additional presentation and discussion will include recommendations from the Substance Use, Abuse and Addiction working group and the Intramural Research Program working group. Time will be allotted both days for presentation and discussion of each Working Group's recommendations. Any supporting documentation for this meeting, including the agenda, will be available at *http://smrb.od.nih.gov.* Sign up for public comment will begin at approximately 7:30 a.m. on both September 14 and 15 and will be restricted to one sign in per person. In the event that time does not allow for all those interested to present oral comments, anyone may file written comments using the contact person's address below.

Place: National Institutes of Health, Building 31, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Time: September 15, 2010, 8 a.m. to 5 p.m.

Agenda: Continuation of September 14th meeting.

Place: National Institutes of Health, Building 31, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Lyric Jorgenson, Health Sciences Policy Analyst Office of Science Policy, Office of the Director, NIH, National Institutes of Health, Building 1, Room 218, MSC 0166, 9000 Rockville Pike, Bethesda, MD 20892, *smrb@mail.nih.gov*, (301) 496–6837.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

The meeting will also be webcast. The draft meeting agenda and other information about the SMRB, including information about access to the webcast, will be available at *http://smrb.od.nih.gov*.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: August 16, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–20675 Filed 8–19–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0423]

ASK (Assess Specific Kinds of CHILDREN Challenges for Neurologic Devices) Study Children Workshop; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop entitled ASK (Assess Specific Kinds of CHILDREN Challenges for Neurologic Devices) Study Children Workshop. The purpose of the public workshop is to solicit comments from academic investigators and clinicians associated with the use, research and/or development of pediatric neuroprostheses regarding approaches for enhancing the protection and promotion of public health in children and adolescents with neuroprostheses. The public workshop will provide an overview of pediatric initiatives across the Agency, neurological and neurosurgical perspectives on medical devices, a review of pediatric assessments and outcome measures, and scientific research issues associated with the use of neuroprotheses in pediatric populations, including cochlear implants, deep brain stimulators, hydrocephalus shunts, spinal cord stimulators, and vagus nerve stimulators. Information from this public workshop will help establish a science-based framework of recommendations to aid in the development of more efficient strategies in evaluating pediatric neuroprostheses regulated by the Agency.

Dates and Time: The public workshop will be held on September 13, 2010, from 9 a.m. to 5 p.m.

Location: The public workshop will be held at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31, Conference Center, rm. 1503, Silver Spring, MD 20993. For lodging and directions, please refer to the meeting on the Internet at: *http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.*

Contact Person: Carlos Peña, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 4264, Silver Spring, MD 20993–0002, 301–796–8521, FAX: 301–847–8617, email: *carlos.pena@fda.hhs.gov*.

Registration: Registration requests must be received by 5 p.m. on September 6, 2010. If you wish to attend the public meeting, you must register online at: *http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm*. There is no registration fee for the public workshop. Early registration is recommended because seating is limited. There will be no onsite registration.

If you wish to make an oral presentation at the workshop, you must indicate this at the time of registration. FDA will do its best to accommodate requests to speak. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and to request time for a joint presentation. FDA will determine the amount of time allotted to each presenter and the approximate time that each oral presentation is scheduled to begin.

If you wish to make an oral presentation during the open comment period at the workshop, you must indicate this at the time of registration. FDA requests that presentations focus on the areas described in this notice. You should also identify which discussion topic you wish to address in